Inhibitory Effect of the Traditional Chinese Medicine Ephedra sinica granules on Streptococcus pneumoniae Pneumolysin
| Autor: | Yan Xu, Yinan Guo, Yibu Kong, Lina Wei, Yanbo Wang, Liping Sun, Lei Guo, Lizhong Ding, Tingting Guo, Xiaozhou Sun |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pharmacology Ephedra sinica A549 cell Pneumolysin ved/biology Toxin ved/biology.organism_classification_rank.species Pharmaceutical Science General Medicine Biology medicine.disease medicine.disease_cause respiratory tract diseases Microbiology 03 medical and health sciences Pneumonia 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Bacteremia Streptococcus pneumoniae medicine Meningitis |
| Zdroj: | Biological and Pharmaceutical Bulletin. 43:994-999 |
| ISSN: | 1347-5215 0918-6158 |
| DOI: | 10.1248/bpb.b20-00034 |
| Popis: | Streptococcus pneumoniae (S. pneumoniae) is an opportunistic pathogen that causes pneumonia, meningitis and bacteremia in humans and animals. Pneumolysin (PLY), a major pore-forming toxin that is important for S. pneumoniae pathogenicity, is a promising target for the development of anti-infective agents. Ephedra sinica granules (ESG) is one of the oldest medical preparation with multiple biological activities (such as a divergent wind and cold effect); however, the detailed mechanism remains unknown. In this study, we found that ESG treatment significantly inhibited the oligomerization of PLY and then reduced the activity of PLY without affecting S. pneumoniae growth and PLY production. In a PLY and A549 cell co-incubation system, the addition of ESG resulted in significant protection against PLY-mediated cell injury. Furthermore, S. pneumoniae-infected mice showed decreased mortality, and alleviated tissue damage and inflammatory reactions following treatment with ESG. Our results indicate that ESG is a potential candidate treatment for S. pneumoniae infection that targets PLY. This finding partially elucidates the mechanism of the Chinese herbal formula ESG in the treatment of pneumococcal disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|